Despite its recent raise, whose size implies at least some affirmation for its model, MD Start believes incubation, generally speaking, has yet to catch on widely in Europe. “I see a lot of interest when we talk to other incubators,” says Guenther. “But they lack the funding, and also often lack the depth of experience, particularly in the regulatory and clinical development area, which is something that we’ve built up over 10 years. For the moment, that makes us unique.”
Anne Osdoit agrees: “We’re not seeing a lot of other initiatives.” In fact, she argues that MD Start is best seen as complementary to the efforts of other European incubator/accelerators such as, for example, the Milan-based venture firm Innogest, which has helped launch a cardiovascular-focused incubator. (See “Innogest and the Virtues of Focused Investing,” MedTechStrategist, February 20, 2019.)
Such efforts are “basically a step before what we do,” she says. “We might actually take over projects from other incubator structures in Europe.”
Most early-stage incubators basically do “sourcing, a little bit of tech transfer, and initial due diligence and de-risking,” she goes on. But they’re often limited in how much they can invest in a project, an issue MD Start III no longer has to worry about. The amount a typical incubator invests “is probably a fraction of what we can put in a seed round,” says Osdoit.
Most incubators are “more focused on identifying projects and helping with the initial steps of the transfer into a company than we are.” MD Start does that “plus development, plus initial clinical trials. I think we have an opportunity to work with all these structures; there hasn’t been something really comparable to us in terms of how far it will take projects.”
“We might actually take over projects from other incubator structures in Europe.”
And if that was true of MD Start I and II, it’s especially true of MD Start III. MD Start III’s third investment, out of an Israeli incubator, is a case in point. “I think a number of Israeli entrepreneurs and investors are finding that the local ecosystem is amazing for starting companies,” Osdoit says. They’re able to get grant money, support, and expertise from executives in the Israeli medtech industry. But over time, “a lot of these companies find themselves in a valley of death between their seed round and their first-in-human, because they raised too little money
in their seed round, or got only a fraction of what they needed to de-risk the project through the public grants.” Thus, she says, “they don’t yet have the milestones that enable them to raise a Series A, and they’re stuck somewhere in the middle. They could keep on piling local money and angels and public money into their project, but it’s not going to get them where they need to be in terms of getting to the US for an early feasibility study, or doing a first-in-human in Europe. At some point they need to go broader and beyond Israel, and that includes funding.”
That’s where an incubator like MD Start can help. Adds Lukas Guenther, “That’s the key. We believe we can increase the likelihood of success because of deep domain expertise during this early stage. We are the ones who de-risk those projects; we aren’t like those investors who say, ‘Come back when you have de-risked it.’”
Fifteen years ago, when he was trying to launch MD Start I, Tim Lenihan recalls, “The first people I talked to were Hanson Gifford [of The Foundry] and Josh Makower [of ExploraMed] to pick their brains over a cup of coffee.” MD Start “has come a long way, for sure,” he says.
MD Start’s recent exit and the amount of money it raised in its most recent iteration is an illustration of how far this experiment in European incubation has come. Anne Osdoit notes that the key to success for MD Start is “finding a structure that enables you to work without constantly fundraising, and without raising the bar too high in terms of how much money you need to return [to investors]. That’s why it’s tricky. When we looked at The Foundry and Coridea [the New York-based incubator that recently signed a deal with Deerfield to form DF Catalyst], it always seemed like it was going to be exhausting to raise money project after project, until we actually had the track record that would lead people to give us money for the shell that would welcome the next project.” MD Start isn’t quite there yet, she says. But the huge fund raised and the exit move in that direction. So does the new structure. “If you do it as a fund, as we have, you make life a bit more difficult in terms of how much you need to return, but you aren’t raising money all the time. There’s a trade-off between having enough money to work for a number of years, but also still make it reasonable in terms of exit expectations.” (For more on Deerfield Catalyst, see “Deerfield Catalyst: Building a New Medtech Ecosystem,” MedTechStrategist, March 10, 2021.)
As to whether the size of MD Start III’s raise or the recent exit is more indicative of the incubator’s success, there are arguments on both sides.
Certainly, it is the raison d’etre of incubators, perhaps even more than a venture fund, to achieve exits, and in the process to validate the early judgement or expertise of the incubator team, both to select projects and to nurture them. Simply raising a lot of money proves neither but speaks to a kind of confidence, earned or not, on the part of other investors. That’s why exits are so important.
"We’ve got 10 healthy companies, all with good data."
But a first exit is also only a snapshot in time. MD Start I, II, and III have launched around 10 companies combined, and there’s still the possibility, if not likelihood, that several if not most of the remaining companies will find their own exits in time, especially since, say many incubator executives, incubators often take longer to realize exits, precisely because they get involved with projects so early. (See “Rainbow Medical: Building an Incubator for the Long Haul,” MedTech Strategist, October 24, 2016.)
Thus, it’s entirely likely that MD Start, having launched about a decade ago, will start to see more exits and fairly soon. And some of those may make the preCARDIA deal—something of an outlier because of Abiomed’s early participation—look small in comparison. “You go out and raise money and after a while, people say, ‘Well, you haven’t had an exit yet,’” says Lukas Guenther. “But I say, ‘We’ve got 10 healthy companies, all with good data. It’s going to happen.’”
Guenther points out that MD Start III was able to raise its latest round “not being able to brag about any exit.” Like Anne Osdoit, he believes that “it will surely help us to raise MD Start IV.” Still, he notes, “the exit came at a good time because it underlines what we’ve been doing all along.”
Related News